A Phase 1 Dose Escalation Study of ARQ 197 in Adult Patients With Advanced/Recurrent Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2017
At a glance
- Drugs Tivantinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Kyowa Hakko Kirin
- 23 Aug 2012 Planned end date changed from 1 Dec 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.
- 01 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.